About the Authors
- Wai-Ping Fung-Leung
-
* E-mail: wleung@its.jnj.com
Affiliation Janssen Research & Development, L.L.C., San Diego, California, United States of America
- Wilson Edwards
-
Affiliation Janssen Research & Development, L.L.C., San Diego, California, United States of America
- Yi Liu
-
Affiliation Janssen Research & Development, L.L.C., San Diego, California, United States of America
- Karen Ngo
-
Affiliation Janssen Research & Development, L.L.C., San Diego, California, United States of America
- Julianty Angsana
-
Affiliation Janssen Research & Development, L.L.C., San Diego, California, United States of America
- Glenda Castro
-
Affiliation Janssen Research & Development, L.L.C., San Diego, California, United States of America
- Nancy Wu
-
Affiliation Janssen Research & Development, L.L.C., San Diego, California, United States of America
- Xuejun Liu
-
Affiliation Janssen Research & Development, L.L.C., San Diego, California, United States of America
- Ronald V. Swanson
-
Affiliation Janssen Research & Development, L.L.C., San Diego, California, United States of America
- Alan D. Wickenden
-
Affiliation Janssen Research & Development, L.L.C., San Diego, California, United States of America
Competing Interests
I have read the journal's policy and the authors of this manuscript have the following competing interests: All authors in this report are employees of the Janssen Research & Development L.L.C. Kv1.3 antagonists Kv261 peptide and Kv261-HSA-34 fusion protein are covered in our patent application US20140255401 titled “Kv1.3 Antagonists and Methods of Use”. For material owned and patented by Janssen, material transfer agreements will be required prior to sharing but this does not alter our adherence to PLOS ONE policies on sharing data and material.
Author Contributions
Conceptualization: WPFL WE ADW RVS. Formal analysis: XJL. Investigation: WPFL ADW WE YL KN JA GC NW. Methodology: WPFL WE ADW. Supervision: WPFL ADW WE RVS. Visualization: WPFL ADW. Writing – original draft: WPFL ADW WE. Writing – review & editing: WPFL ADW WE.